Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia

@article{Lecrubier2001ConsensusOT,
  title={Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia},
  author={Yves Lecrubier and Michel Azorin and Thierry Bottai and Jean Dal{\'e}ry and G. Garreau and Th{\'e}r{\`e}se Lemp{\'e}ri{\`e}re and A. Lisoprawski and François Petitjean and J. M. Vanelle},
  journal={Neuropsychobiology},
  year={2001},
  volume={44},
  pages={41 - 46}
}
Clinical expectations in schizophrenia treatment have greatly increased since the introduction of new atypical antipsychotics, but the choice of therapeutic strategy has become more complex and reference guidelines are scarce. This paper summarizes the consensus of a broad range of professionals after long-term commercialization in France of an atypical antipsychotic, amisulpride. Participants were from psychiatric hospitals, private clinics, out-patients settings and research; all were… Expand
Augmentation With Amisulpride for Schizophrenic Patients Nonresponsive to Antipsychotic Monotherapy
TLDR
It is suggested that amisulpride may be a promising option as an augmentation strategy in treatment-resistant schizophrenic patients and require confirmation in a randomized controlled trial. Expand
An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective Disorders.
TLDR
The combination of amisulpride with atypical antipsychotics is a promising option in patients who are resistant to treatment and shows significant improvement in negative symptoms, positive symptoms, cognition especially in old chronic schizophrenics. Expand
An Open Label Study on Amisulpride In Augmentation with Atypical Antipsychotics in Treatment Resistant Schizophrenia and Schizoaffective Disorders
The authors report an open label study in treatment resistant patients of schizophrenia,schizoaffective disorders.The patients who were earlier being treated with atypical antipsychotics, were put onExpand
Use of Amisulpride in a Psychiatric Outpatient Clinic in Hong Kong
TLDR
Amisulpride appears to be an effective antipsychotic medication for Chinese patients treated in an outpatient clinic, with few side effects. Expand
Investigational drugs for anxiety in patients with schizophrenia
TLDR
In spite of ancient positive results and a strong rationale, aripiprazole and related compounds were not in recent clinical trials, and the authors believe that these compounds deserve more attention. Expand
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open- label study
TLDR
Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia. Expand
Cost analysis of treating schizophrenia with amisulpride: Naturalistic mirror image study
TLDR
Amisulpride treatment may lead to a reduction in the cost of treating schizophrenia in comparison with treatment with other antipsychotic medications, and the clinical and quality of life scores improved during the year of treatment with amisul Pride. Expand
Switching atypical antipsychotics: a review
TLDR
There is a rationale for their early use to avoid the practical problems associated with switching from conventional antipsychotics as well as the opportunity to maintain patients on an optimal atypical antipsychotic monotherapy. Expand
Switching Antipsychotic Medications: General Recommendations and Switching to Amisulpride
TLDR
A retrospective questionnaire among 60 patients switching to amisulpride treatment was undertaken to identify the characteristics of patients switching antipsychotics and their reasons, with lack of efficacy, adverse events and treatment optimisation before reintegration being the most common reasons. Expand
The use of Atypical antipsychotics in French psychiatric hospitals
TLDR
In bipolar disorders, AAPs seem more likely to be associated to an ongoing therapy using mood stabilizer than to replace it, underlines the significant place taken by AAP for the treatment of psychiatric diseases in hospital prescribing practices. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 13 REFERENCES
Treatment of negative symptoms in schizophrenia with amisulpride.
TLDR
Negative symptoms can be improved by low doses of amisulpride, favouring the hypothesis of dopaminergic hypofunction as one of the causes of negative symptoms. Expand
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
TLDR
Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia, and both treatments were equally effective against positive symptoms on the PANSS positive syndrome subscale. Expand
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.
TLDR
Amisulpride is effective in the medium-term treatment schizophrenic patients with predominantly negative symptoms of schizophrenia and all efficacy assessments were statistically in favour of amisul Pride compared with placebo. Expand
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
TLDR
These findings confirm and extend those of earlier placebo-controlled studies of low-dose amisulpride in the treatment of patients with predominantly negative symptoms of schizophrenia. Expand
Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol
This 4‐week, double‐blind, randomized study was undertaken to determine the dose‐response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia. Fixed doses ofExpand
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
TLDR
Amisulpride is at least as effective as haloperidol in the treatment of acute exacerbations of schizophrenia, and is more effective in the Treatment of negative symptoms whilst causing less parkinsonism. Expand
Safety of amisulpride (Solian): a review of 11 clinical studies.
TLDR
The overall laboratory safety profile of amisulpride did not show clinically relevant abnormalities in liver function tests nor haematological abnormalities, and was superior to standard reference compounds. Expand
Long‐term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
&NA; Amisulpride is an atypical antipsychotic with selective affinity for dopamine D2/D3 receptors. In this long‐term, open, randomised, multicentre trial, patients with chronic or subchronicExpand
Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist
TLDR
ASP appears to be as effective as FPX with regard to antipsychotic effects on positive schizophrenic symptomatology, while extrapyramidal tolerability is better. Expand
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
TLDR
This pharmacological profile of amisulpride, characterized by a preferential blockade of effects involving presynaptic mechanisms and limbic structures, may explain the clinical efficacy of this drug against both negative and positive symptoms of schizophrenia and its low propensity to produce extrapyramidal side effects. Expand
...
1
2
...